OVARIAN CANCER and US: nccn guidelines

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label nccn guidelines. Show all posts
Showing posts with label nccn guidelines. Show all posts

Tuesday, March 20, 2012

Controversies Continue in NCCN Ovarian Cancer Guidelines



Controversies Continue in NCCN Ovarian Cancer Guidelines

Medscape Medical News from the:  

National Comprehensive Cancer Network (NCCN) 17th Annual Conference

This coverage is not sanctioned by, nor a part of, the National Comprehensive Cancer Network.

From Medscape Medical News > Conference News

Controversies Continue in NCCN Ovarian Cancer Guidelines

Neoadjuvant Chemotherapy and CA-125 Reviewed


 
March 20, 2012 (Hollywood, Florida) — The ovarian cancer guidelines from the National Comprehensive Cancer Network (NCCN) address a number of ongoing controversies, according to a presenter here at the NCCN 17th Annual Conference.
 
"There have not been a lot of changes in the past year, but there are various areas of controversy in the guidelines," Robert Morgan, MD, from the City of Hope Comprehensive Cancer Center in Los Angeles, California, told Medscape Medical News at the conference.
One such controversy is about the usefulness of the biomarker CA-125 to monitor patients who have been treated with surgery and/or chemotherapy. Dr. Morgan called CA-125 the "most controversial" aspect of patient follow-up.......

New NCCN Guidelines on Cancer Care for Teens, Young Adults



New NCCN Guidelines on Cancer Care for Teens, Young Adults

March 19, 2012 (Hollywood, Florida) — Since 1975, adults older than 44 years and children younger than 15 years have had significant improvements in cancer survival in the United States, but there has been no such improvement seen in the survival of adolescents and young adults (aged 15 - 39 years) with cancer, according to new research presented here at the National Comprehensive Cancer Network (NCCN) 17th Annual Conference......

Saturday, March 17, 2012

Lynch Syndrome: Don't Miss It (Transcript including slides))



Blogger's Opinion/Note:
guidelines indicate varying ages of screening depending on organ assuming there are screening mechanisms (eg. ovarian cancer has no screening for the general population however increased surveillance is possible for those at high risk,  albeit, ineffective; generally 25 yrs +;  'averages' are not helpful and therefore the urging of family history taking by primary/family care physicians, see NCCN guidelines for Lynch Syndrome which includes gene-specific details (eg. MLH1, MSH2/6, PMS2.....)

Lynch Syndrome: Don't Miss It (Transcript)

Clinical Implications

"Lynch syndrome is a genetic defect that has significant implications on the clinical side. A patient whose genetic testing is positive for Lynch syndrome has a likelihood of developing colon cancer that approaches 70% over his or her lifetime. The risk for uterine cancer is similar or a bit higher, and the risk for ovarian cancer is13%-15%. Almost certainly, these patients will have some type of cancer during their lifetime.

Metachronous cancers occur in 7%-10% of patients with Lynch syndrome. These patients present with one cancer, and typically in the course of a short period of time, another cancer develops. In patients with Lynch syndrome who have colon cancer, if you don't perform a subtotal colectomy because you didn't recognize that it was Lynch syndrome, the likelihood that the patient will develop a repeat colon cancer over 30 years (even in patients who are being screened) approaches 65%. This is not uncommon. A lot of these diagnoses are missed, and a secondary cancer develops."

"You need to start thinking about syndromic cancers because the relative risk is quite high. You need to be thinking about this in patients with early cancers -- not just colon cancer, but in uterine cancer and ovarian cancer as well." (Blogger's Note: and others including pancreatic, stomach, ureter, renal, bilary tract, gallbladder.....see slides)

" If you look at colon cancer in Lynch syndrome, the average age of onset is earlier (45 years) and some patients may be in their 20s. For sporadic uterine cancer, the average age is approximately 60 years, but in Lynch syndrome, it is shifted by a decade, to 50 years. When you see these cancers in a younger patient, the bell should go off and you should start thinking about Lynch syndrome and doing the appropriate testing."

"It is important to think about extracolonic cancers in these patients and to start to put the dots together because we are missing the boat on a lot of these syndromic cancers. It's not a zebra; it's 2%-3% of the patients who are presenting with cancer. We need to think outside the box. Even if you are not a gastroenterologist, include the colon when you see syndromic related cancers of the uterus, ovary, small bowel, or stomach."

Friday, February 10, 2012

2012 Recently updated NCCN Clinical Practice Guidelines in Oncology™ plus link to Ovarian Cancer (and other related) NCCN guidelines



Blogger's Note: Lynch Syndrome is included in the Colorectal Cancer section (*see below)

NCCN Guidelines for Treatment of Cancer by Site

  • Bone Cancer Version 2.2012
  • Breast Cancer Version 1.2012
  • Colon Cancer Version 3.2012
  • Hodgkin Lymphoma Version 1.2012
  • Non-Hodgkin's Lymphomas Version 1.2012
  • Rectal Cancer Version 3.2012
  • Testicular Cancer Version 1.2012
  • Waldenström's Macroglobulinemia / Lymphoplasmacytic Lymphoma Version 1.2012
  • Cancer Related Fatigue (and others)

NCCN Guidelines for Supportive Care

  • Distress Management Version 1.2012
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

NCCN Guidelines for Treatment of Cancer by Site (professional)

You must Login or Register to access this information.

Occult Primary (Cancer of Unknown Primary) You Must Login First to Access Physician Guideline


Ovarian Cancer You Must Login First to Access Physician Guideline Access the Patient Guidelines CME You Must Login First to Access Physician Guideline

  • Epithelial Ovarian Cancer (including Fallopian Tube Cancer and Primary Peritoneal Cancer)
  • Borderline Epithelial Ovarian Cancer (Low Malignant Potential)
  • Less Common Ovarian Histologies

Fallopian Tube Cancer (See Ovarian Cancer)

Primary Peritoneal Cancer (See Ovarian Cancer

          ~~~~~~~~~~~~~~~~~~~~~



NCCN Guidelines for Detection, Prevention, &  Risk Reduction (*includes genetic syndromes, supportive care):



Colorectal Cancer Screening Open Physician Guideline Access International Translation of Physician Guideline

Genetic/Familial High-Risk Assessment: Breast and Ovarian Open Physician Guideline

  • Breast and/or Ovarian Genetic Assessment
  • Hereditary Breast and/or Ovarian Cancer
  • Li-Fraumeni Syndrome
  • Cowden Syndrome

Thursday, August 19, 2010

NCCN Clinical Practice Guidelines in Oncology



Ovarian Cancer
You Must Login First (free)

* Epithelial Ovarian Cancer (including Fallopian Tube Cancer and Primary Peritoneal Cancer)
* Borderline Epithelial Ovarian Cancer (Low Malignant Potential)
* Less Common Ovarian Histologies